BioNTech Announces Strategic Acquisition of CureVac

The latest announcement is out from BioNTech SE ( (BNTX) ).

On June 12, 2025, BioNTech SE announced a strategic acquisition of CureVac N.V., a clinical-stage biotech company, through a public exchange offer. This all-stock transaction aims to strengthen BioNTech’s capabilities in mRNA-based cancer immunotherapy and marks a significant milestone in their oncology strategy. The acquisition, supported by CureVac’s major shareholders and expected to close in 2025, is anticipated to create long-term value for shareholders by combining complementary scientific capabilities and proprietary technologies. The transaction has been unanimously approved by both companies’ management and supervisory boards and is subject to regulatory approvals and customary closing conditions.

The most recent analyst rating on (BNTX) stock is a Buy with a $171.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.

Spark’s Take on BNTX Stock

According to Spark, TipRanks’ AI Analyst, BNTX is a Neutral.

BioNTech’s strong balance sheet and positive technical momentum are offset by profitability challenges and financial losses highlighted in the earnings call. Strategic investments in oncology could drive future growth, but current financial risks weigh on the overall score.

To see Spark’s full report on BNTX stock, click here.

More about BioNTech SE

BioNTech SE is a global next-generation immunotherapy company focused on pioneering novel investigative therapies for cancer and other serious diseases. It utilizes a wide array of computational discovery and therapeutic modalities to rapidly develop novel biopharmaceuticals. The company has a diversified portfolio of oncology product candidates, including mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies such as antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) T cell therapies. BioNTech is also involved in developing multiple mRNA vaccine candidates for infectious diseases, leveraging its expertise in mRNA development and in-house manufacturing capabilities.

Average Trading Volume: 1,200,372

Technical Sentiment Signal: Buy

Current Market Cap: $25.7B

See more insights into BNTX stock on TipRanks’ Stock Analysis page.